Jefferies Financial Group Inc. Takes $7.37 Million Position in Insulet Corporation $PODD

Key Points

• Jefferies Financial Group bought 48,416 Insulet shares worth approximately $7.37 million, giving it a 0.07% stake. Director Timothy C. Stonesifer also increased his holdings by 44.6% through a $400,393 stock purchase.
• Insulet reported stronger-than-expected quarterly results, with EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million, up 23.5% year over year.
• Analyst sentiment is mixed: the stock carries a consensus “Hold” rating with an average price target of $195.40, while investors also face potential litigation tied to alleged manufacturing and quality-control disclosures.

Jefferies Financial Group Inc. purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 48,416 shares of the medical instruments supplier's stock, valued at approximately $7,371,000. Jefferies Financial Group Inc. owned about 0.07% of Insulet at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Larson Financial Group LLC boosted its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet during the fourth quarter worth $26,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of Insulet during the 4th quarter valued at $29,000.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.36% of the company's stock.

Insulet Stock Performance

NASDAQ PODD opened at $143.41 on Friday. The company has a market capitalization of $9.95 billion, a price-to-earnings ratio of 26.81, a PEG ratio of 1.13 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The stock has a fifty day simple moving average of $154.47 and a 200 day simple moving average of $181.40.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business's quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts expect that Insulet Corporation will post 6.51 EPS for the current year.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Wall Street Analyst Weigh In

PODD has been the topic of a number of research reports. William Blair initiated coverage on Insulet in a research report on Wednesday, May 20th. They set an "outperform" rating on the stock. The Goldman Sachs Group reiterated a "buy" rating and issued a $205.00 target price on shares of Insulet in a research report on Wednesday, May 27th. Raymond James Financial reissued an "outperform" rating and set a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Wall Street Zen cut Insulet from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Insulet has a consensus rating of "Hold" and an average target price of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.